NautaDutilh assisted Immatics N.V. with their USD 150 million underwritten offering of ordinary shares and pre-funded warrants. Immatics currently intends to use the net proceeds of this offering primarily to fund research and development expenses for its late-stage clinical programs, the expansion of a sales and marketing team in the U.S. and related commercialisation expenses, as well as for working capital and general corporate purposes. Immatics’ ordinary shares are listed on NASDAQ (IMTX).
“We have greatly appreciated working with Davis Polk & Wardwell on this transaction, which marks yet another milestone for the company that we hope will enable Immatics to advance their business even further.”
The NautaDutilh team further consisted of Nina Kielman, Marloes van der Laan and Simon Houberg.
